Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes
Journal of Clinical Medicine · 14.07.2026 · 15 (14) · 5509
DOI: 10.3390/jcm15145509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.07.2026. Verfasst von Silvia Calabria und 5 weiteren Autor:innen. Beteiligte Einrichtung: CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Almirall S.p.A..
Abstract (Originalsprache)
Background/Objectives: Psoriasis is a chronic inflammatory skin disease leading to substantial psycho-physical and social burden and reduced quality of life. Biologic agents have transformed its therapeutic landscape. This real-world Italian study described the pattern of treatment with biologic drugs in patients with psoriasis.
Methods
A retrospective observational study was conducted using administrative databases from Italian Local Health Units, covering nearly 12 million individuals. The study included adults with psoriasis identified from January 2015 to March 2025 by hospitalization, co-payment exemption code, or topical anti-psoriatic prescriptions. Patients initiating a biologic drug (anti-TNFα, anti-IL12/23, anti-IL17, and anti-IL23) were selected and further analyzed in terms of treatment switching, drug survival, and healthcare resource utilization and related costs within the first year after biologic initiation, and compared.
Results
A total of 10,270 biologic-naïve adult patients was included in the analysis (anti-TNFα N = 5078; anti-IL12/23 N = 767; anti-IL17 N = 2574; anti-IL23 N = 1851). Most patients (95.0%) starting an anti-IL23 agent did not switch. Compared with anti-TNFα, initiating an anti-IL23 inhibitor was associated with a significant reduced risk of switching (HR = 0.186; 95%CI: 0.144–0.240; p < 0.001). According to the cost analysis stratified by switching status, remaining on the index biologic was associated with a lower economic burden. Although differences between switchers vs. non-switchers among anti-IL23 users did not reach statistical significance (€12,052 vs. €11,406, respectively, p = 0.132), data support the economic advantage associated with greater treatment stability.
Conclusions
Anti-IL23 agents showed effective, durable first-line use with potential long-term clinical and economic benefits in moderate-to-severe psoriasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy.
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy.
- Department of Dermatology, University of Rome Tor Vergata, 00133 Rome, Italy.
- Research Centre on Public Health, University of Milano-Bicocca, 20900 Monza, Italy.
ORCID-Profile: Silvia Calabria, Paolo Gisondi, Marina Talamonti, Chiara Veronesi, Luca Degli Esposti
Förderung
- Almirall S.p.A.
Zitieren
APA
Calabria, S., Gisondi, P., Talamonti, M., Mantovani, L. G., Veronesi, C., & Degli Esposti, L. (2026). Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes. Journal of Clinical Medicine, 15(14), 5509. https://doi.org/10.3390/jcm15145509
Vancouver
Calabria S, Gisondi P, Talamonti M, Mantovani LG, Veronesi C, Degli Esposti L. Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes. Journal of Clinical Medicine. 2026;15(14):5509. doi:10.3390/jcm15145509
BibTeX
@article{Calabria2026,
author = {Calabria, Silvia and Gisondi, Paolo and Talamonti, Marina and Mantovani, Lorenzo Giovanni and Veronesi, Chiara and Degli Esposti, Luca},
title = {Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5509},
doi = {10.3390/jcm15145509}
}
EUVIMED